{"filing":{"accession_number":"0001759138-26-000041","cik":"0001759138","ticker":"CABA","company_name":"Cabaletta Bio, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"caba-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000041/caba-20260914.htm"},"events":[{"id":33143,"run_id":30468,"accession_number":"0001759138-26-000041","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The disclosure reports the exercise of 53.1 million common stock warrants issued in June 2025, resulting in approximately $128.2 million in aggregate gross proceeds through the September 12, 2026 expiration date. While technically a warrant exercise rather than a new issuance, this represents a material dilutive capital event that increased the company's equity base and raised substantial cash. The magnitude ($128.2 million) and the concentration of exercises in the final quarter (46 million warrants, $115 million) indicate material shareholder dilution and capital activity warranting disclosure.","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36511,"accession_number":"0001759138-26-000041","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports the exercise of 53.1 million common stock warrants issued in June 2025, resulting in approximately $128.2 million in aggregate gross proceeds through the September 12, 2026 expiration date. While technically a warrant exercise rather than a new issuance, this represents a material dilutive capital event that increased the company's equity base and raised substantial cash. The magnitude ($128.2 million) and the concentration of exercises in the final quarter (46 million warrants, $115 million) indicate material shareholder dilution and capital activity warranting disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:03:47.008864+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36511,"accession_number":"0001759138-26-000041","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports the exercise of 53.1 million common stock warrants issued in June 2025, resulting in approximately $128.2 million in aggregate gross proceeds through the September 12, 2026 expiration date. While technically a warrant exercise rather than a new issuance, this represents a material dilutive capital event that increased the company's equity base and raised substantial cash. The magnitude ($128.2 million) and the concentration of exercises in the final quarter (46 million warrants, $115 million) indicate material shareholder dilution and capital activity warranting disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:03:47.008864+00:00","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-09-14"}]}